# David Dai from UBS maintained a Buy rating on Telix Pharmaceuticals, with a price target of A$31.00.

*business · news · 2026-04-08 · Markets Insider*

## Key points

- UBS analyst David Dai maintained a Buy rating on Telix Pharmaceuticals with a A$31.00 target.
- Telix Pharmaceuticals reported A$630.94 million in revenue but a GAAP net loss of A$7.38 million.
- Last year, Telix had a net profit of A$38.24 million, indicating a shift to a net loss.
- Canaccord Genuity also issued a Buy rating on Telix Pharmaceuticals in a recent report.

**Companies:** Telix Pharmaceuticals

[Read the full story on Markets Insider](https://markets.businessinsider.com/news/stocks/telix-pharmaceuticals-tlppf-gets-a-buy-from-ubs-1036002092)

---

Canonical: https://newsio.io/n/c949e5e0-9c30-4d68-b324-615b1f62d1f8/david-dai-from-ubs-maintained-a-buy-rating-on-telix-pharmaceuticals-with-a-price
Summarized by Newsio from Markets Insider. https://newsio.io/how-it-works